| A systematic review of coverage decision-making on health technologies—Evidence from the real world KE Fischer Health Policy, 2012 | 78 | 2012 |
| Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia KE Fischer, T Heisser, T Stargardt Health Policy 120 (10), 1115-1122, 2016 | 56 | 2016 |
| Service quality and perceived customer value in community pharmacies D Guhl, KE Blankart, T Stargardt Health services management research 32 (1), 36-48, 2019 | 50 | 2019 |
| Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes KE Fischer BMC medical informatics and decision making 12, 1-13, 2012 | 41 | 2012 |
| Early benefit assessment of pharmaceuticals in Germany: manufacturers’ expectations versus the Federal Joint Committee’s decisions KE Fischer, T Stargardt Medical Decision Making 34 (8), 1030-1047, 2014 | 39 | 2014 |
| Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis KE Fischer, WH Rogowski, R Leidl, B Stollenwerk Health Policy 112 (3), 187-196, 2013 | 26 | 2013 |
| The diffusion of generics after patent expiry in Germany KE Fischer, T Stargardt The European Journal of Health Economics 17, 1027-1040, 2016 | 23 | 2016 |
| The role of health technology assessment in coverage decisions on newborn screening KE Fischer, SD Grosse, WH Rogowski International journal of technology assessment in health care 27 (4), 313-321, 2011 | 22 | 2011 |
| The impact of physician-level drug budgets on prescribing behavior KE Fischer, T Koch, K Kostev, T Stargardt The European Journal of Health Economics 19 (2), 213-222, 2018 | 18 | 2018 |
| Funding Decisions for Newborn Screening: A Comparative Review of 22 Decision Processes in Europe KE Fischer, WH Rogowski International Journal of Environmental Research and Public Health 11 (5 …, 2014 | 17 | 2014 |
| Do medicine shortages reduce access and increase pharmaceutical expenditure? A retrospective analysis of Switzerland 2015-2020 KE Blankart, S Felder Value in Health 25 (7), 1124-1132, 2022 | 16 | 2022 |
| A structured tool to analyse coverage decisions: development and feasibility test in the field of cancer screening and prevention KE Fischer, R Leidl, WH Rogowski Health Policy 101 (3), 290-299, 2011 | 15 | 2011 |
| Link between process and appraisal in coverage decisions: an analysis with structural equation modeling KE Fischer, B Stollenwerk, WH Rogowski Medical Decision Making 33 (8), 1009-1025, 2013 | 9 | 2013 |
| The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany KE Blankart, T Stargardt Health Economics 29, 63-82, 2020 | 8 | 2020 |
| Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany KE Blankart, F Arndt International Journal of Environmental Research and Public Health 17 (11), 4113, 2020 | 8 | 2020 |
| Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark G Hostenkamp, KE Fischer, K Borch-Johnsen Health Policy 120 (12), 1404-1411, 2016 | 8 | 2016 |
| Improving Service Provision - The Health Care Services' Perspective E Winter, V., Thomsen, M, Schreyögg, J, Blankart, K, Duminy, L ... Journal of Service Management Research 3 (4), 163-183, 2019 | 6 | 2019 |
| Analysing coverage decision-making: opening Pandora’s box? KE Fischer, R Leidl The European Journal of Health Economics 15, 899-906, 2014 | 6 | 2014 |
| Are patients more adherent to newer drugs? KE Blankart, FR Lichtenberg Health care management science 23 (4), 605-618, 2020 | 5 | 2020 |
| The Effects of Off-label Drug Use on Disability and Medical Expenditure KE Blankart, FR Lichtenberg National Bureau of Economic Research, 2022 | 3 | 2022 |
Tom StargardtProfessor for Health Care ManagementVerified email at uni-hamburg.de
